MW
4,731.4 g/mol
Purity
>99%
Metabolic
RETATRUTIDE
Triple GIP / GLP-1 / Glucagon Receptor Agonist
Synthetic unimolecular peptide engineered to activate the GIP, GLP-1, and glucagon receptors
$125
Per vial · Research use only · COA available
Compound Profile
| Appearance | Lyophilized white powder |
| Molecular Weight | 4,731.4 g/mol |
| Amino Acids | 39 (modified peptide backbone) |
| Dosage | 10 mg |
| Volume | 3 mL |
| Solubility | Bacteriostatic water |
| Purity | ≥98% (HPLC-UV-MS verified) |
| Storage | −20°C long-term · 4°C short-term · Protect from light |
COA, sterility, endotoxin, and heavy metal test results available upon request.
For Research Use Only. This product is not for human consumption, clinical use, or veterinary use. Must be 21+ to purchase. Not evaluated or approved by the FDA for any therapeutic use. Introduction into humans or animals is strictly prohibited by law.
Overview
About RETATRUTIDE
Retatrutide is a novel unimolecular peptide engineered to activate three distinct metabolic receptors — GIP, GLP-1, and glucagon — in a single molecule. Built on a modified peptide backbone with a fatty-acid moiety for extended half-life, it is studied as a next-generation multi-agonist for metabolic and body-composition research, building on the single- and dual-agonist incretin research that preceded it.
Mechanism of Action
How It Works
Retatrutide's triple-receptor activity combines GLP-1 and GIP-mediated glucose-dependent insulin secretion and appetite regulation with glucagon-receptor activity, studied for its contribution to increased energy expenditure — a mechanism distinct from GLP-1/GIP dual agonists. The attached fatty-acid moiety promotes albumin binding, extending circulating half-life and supporting sustained receptor engagement in research models.
Scientific Literature
Research Highlights
Triple agonism at GIP, GLP-1, and glucagon receptors in a single molecule
Glucagon-receptor component studied for added energy-expenditure effects beyond incretin-only agonists
Extended half-life via fatty-acid-mediated albumin binding
Studied in body-composition and metabolic-rate research models
Glucose-dependent insulinotropic activity studied via combined GIP/GLP-1 pathways
Appetite and satiety signaling studied via central and peripheral GLP-1 receptor activity
Subject of ongoing comparative research against single- and dual-incretin-agonist compounds
Research Disclaimer: All research highlights are derived from published preclinical, in vitro, and animal studies. Results observed in laboratory models may not translate to human outcomes. Genfinite makes no claims regarding therapeutic efficacy. All products are sold strictly for scientific research purposes only.
Handling
Storage & Reconstitution
Dry Storage
Store lyophilized powder at −20°C, away from light and moisture. Do not open until ready to use. Shelf life is significantly extended by proper dry storage.
Reconstitution
Reconstitute using Bacteriostatic water. Add solvent slowly to the side of the vial and allow to dissolve gently. Do not shake vigorously.
Post-Reconstitution
Store reconstituted solution refrigerated at 4°C. Use within your laboratory's established timeframe. Do not refreeze after reconstitution.
